

Exhibit A

The Parties' Proposed Constructions of Disputed Claim Terms and Supporting Evidence
for U.S. Patent No. 8,450,475

Disputed Claim Terms	Claim No.	Allergan's Proposed Construction	Allergan's Supporting Evidence	Defendants' Proposed Construction	Defendants' Supporting Evidence
uncrosslinked HA	(Claims 1, 2, 4, 9, 18, 31, 33, 34, 36)	water soluble HA (i.e., uncrosslinked HA and/or lightly crosslinked HA)	<u>INTRINSIC</u> Claims 1-3, 9, 10, 12-16, 18, 19, 27-31, 33, 34, 36, Abstract, Col. 1, l. 66 to Col. 2, l. 6, Col. 2, ll. 15-19, Col. 3, ll. 7-21, Col. 3, l. 54 to Col. 4, l. 3, Col. 4, ll. 4-27, 36-40, Col. 5, ll. 5-13, 15-21, 47-58, Col. 6, ll. 23-35, Col. 6, l. 66 to Col. 7, l. 3, Col. 7, ll. 4-35, Col. 8, ll. 13-22, 50-63, Col. 8, l. 61 to Col. 9, l. 8, Col. 11, ll. 45-56, Col. 13, ll. 9-10, Col. 17, ll. 1-25, Col. 18, ll. 14-21, Example 2, Col. 13, ll. 9-18.	water soluble HA (i.e., uncrosslinked HA and/or lightly crosslinked HA) that is added to the crosslinked HA portion of the composition	<u>INTRINSIC</u> 3:10-13; 5:5-13; 7:6-9; 7:29-35; 13:8-26 Communications from file wrapper of Application No. 12/393,768 including: Office Action dated 5/31/2011; Response to Office Action dated 11/9/2011;

			<p>Communications from file wrapper of Application No. 12/393,768 including: Office Action dated 5/31/2011; Response to Office Action dated 11/9/2011; Office Action dated 2/3/2012; Response to Office Action dated 7/30/2012; Office Action dated 11/19/2012; Applicant Initiated Interview Summary on 2/6/2013; Response to Final Office Action dated 2/19/2013.</p> <p><u>EXTRINSIC</u> VAL0037758-64</p>		<p>Office Action dated 2/3/2012; Response to Office Action dated 7/30/2012; Office Action dated 11/19/2012; Applicant Initiated Interview Summary on 2/6/2013; Response to Final Office Action dated 2/19/2013.</p> <p><u>EXTRINSIC</u> VAL0060472 at 75 (5:1-26)</p>
free HA	(Claims 27-29)	water soluble HA (i.e., uncrosslinked HA and/or lightly	<p><u>INTRINSIC</u> Claims 1-3, 9, 10, 12-16, 18, 19, 27-31, 33, 34, 36, Abstract, Col. 1, l. 66 to Col. 2, l. 6,</p>	water soluble HA (i.e., uncrosslinked HA and/or lightly	<p><u>INTRINSIC</u> 3:10-13; 5:5-13; 7:6-9;</p>

		crosslinked HA)	<p>Col. 2, ll. 15-19, Col. 3, ll. 7-21, Col. 3, l. 54 to Col. 4, l. 3, Col. 4, ll. 4-27, 36-40, Col. 5, ll. 5-13, 15-21, 47-58, Col. 6, ll. 23-35, Col. 6, l. 66 to Col. 7, l. 3, Col. 7, ll. 4-35, Col. 8, ll. 13-22, 50-63, Col. 8, l. 61 to Col. 9, l. 8, Col. 11, ll. 45-56, Col. 13, ll. 9-10, Col. 17, ll. 1-25, Col. 18, ll. 14-21, Example 2, Col. 13, ll. 9-18.</p> <p>Communications from file wrapper of Application No. 12/393,768 including: Office Action dated 5/31/2011; Response to Office Action dated 11/9/2011; Office Action dated 2/3/2012; Response to Office Action dated 7/30/2012; Office Action dated 11/19/2012;</p>	crosslinked HA) that is added to the crosslinked HA portion of the composition	<p>7:29-35; 13:8-26</p> <p>Communications from file wrapper of Application No. 12/393,768 including: Office Action dated 5/31/2011; Response to Office Action dated 11/9/2011; Office Action dated 2/3/2012; Response to Office Action dated 7/30/2012; Office Action dated 11/19/2012; Applicant Initiated Interview Summary on 2/6/2013;</p>
--	--	--------------------	--	---	--

			Applicant Initiated Interview Summary on 2/6/2013; Response to Final Office Action dated 2/19/2013. <u>EXTRINSIC</u> VAL0037758-64		Response to Final Office Action dated 2/19/2013. <u>EXTRINSIC</u> VAL0060472 at 75 (5:1-26)
HA crosslinked with 1,4-butanediol diglycidyl ether (BDDE) hyaluronic acid (HA) component crosslinked with 1,4-butanediol diglycidyl ether (BDDE) (BDDE)-crosslinked	(Claims 1, 31, 34) (Claim 18) (Claim 27)	HA that forms a macromolecular structure resulting from chemical linking of HA by BDDE	<u>INTRINSIC</u> Claims 1, 4-7, 9, 10, 18, 19, 27, 31, 34, Col. 1, ll. 23-34, Col. 1, l. 66 to Col. 2, l. 6, Col. 2, ll. 7-19, 50-58, Col. 3, ll. 7-41, Col. 3, l. 61 to Col. 4, l. 27 Col. 4, ll. 62-65, Col. 5, ll. 5-13, Col. 5, ll. 47-58, Col. 6, ll. 55-65, Col. 7, ll. 20-35, 47-53, Col. 9, ll. 6-33, 40-56, Col. 9, l. 66 to Col. 10, l. 9. Col. 12, ll. 17-49, Col. 16, ll. 40-46, 56-61, Col. 18, ll. 14-21.	HA that has been covalently modified with BDDE to form a macromolecular structure that is water-insoluble, such that the degree of crosslinking is at least about 2% and is up to about 20% “Degree of crosslinking” as used herein has	<u>INTRINSIC</u> 2:15-19; 3:10-19; 4:4-6; 4:62 – 5:4; 7:4-35; 7:49-53; 9:25-39; 12:37-39 U.S. Patent No. 8124120 B2 Communications from file wrapper of Application No. 12/393,768

hyaluronic acid			<p>Communications from file wrapper of Application No. 12/393,768 including: Office Action dated 5/31/2011; Response to Office Action dated 11/9/2011; Office Action dated 2/3/2012; Response to Office Action dated 7/30/2012; Office Action dated 11/19/2012; Applicant Initiated Interview Summary on 2/6/2013; Response to Final Office Action dated 2/19/2013.</p> <p><u>EXTRINSIC</u> Merriam-Webster Online Dictionary and Thesaurus, (http://www.merriamwebster.com/). [AGNHA00096828-96829]</p> <p>Random House Webster's College Dictionary, 2nd edition, 2001, page 296.</p>	the same construction as agreed by the parties.	<p>including: Office Action dated 5/31/2011; Response to Office Action dated 11/9/2011; Office Action dated 2/3/2012; Response to Office Action dated 7/30/2012; Office Action dated 11/19/2012; Applicant Initiated Interview Summary on 2/6/2013; Response to Final Office Action dated 2/19/2013.</p> <p><u>EXTRINSIC</u> VAL0060472</p>
-----------------	--	--	--	---	---

			[AGNHA00096824]		<p>at 73 (2:9-16)</p> <p>VAL0059980 at 81 (2:26-30)</p> <p>VAL0060006 at VAL0060008 (3:14-18), VAL0060013 (8:1-9)</p> <p>VAL0060285 at 87 ([0011])</p>
stable	(Claims 1, 18, 27, 31, 34)	resists chemical and physical decomposition	<u>INTRINSIC</u> Claims 1, 10, 18, 19, 27, 31, 34, Abstract, Col. 1, ll. 42-59, Col. 2, ll. 7-32, 42-48 Col. 3, ll. 42-46, Col. 4, ll. 41-48, Col. 5, ll. 31-46, Col. 6, ll. 23-31, 55-65, Col. 7, ll. 42-64, Col. 8, ll. 4-13, Col. 10, ll. 15-33, Col. 11, ll. 14-44,	A sterile composition that maintains one of the following aspects: transparent appearance, pH, extrusion force and/or rheological characteristics, hyaluronic acid (HA)	<u>INTRINSIC</u> 3:41-46; 4:41-48; 5:39-44; 8:4-13; 13:19-26; 14:1-24 Communications from file wrapper of Application No. 12/393,768

			<p>Col. 13, l. 27 to Col. 14, l. 1-23.</p> <p>Examples 2 & 3.</p> <p>Communications from file wrapper of Application No. 12/393,768 including:</p> <p>Office Action dated 5/31/2011;</p> <p>Response to Office Action dated 11/9/2011;</p> <p>Office Action dated 2/3/2012;</p> <p>Response to Office Action dated 7/30/2012;</p> <p>Office Action dated 11/19/2012;</p> <p>Applicant Initiated Interview Summary on 2/6/2013;</p> <p>Response to Final Office Action dated 2/19/2013.</p> <p><u>EXTRINSIC</u></p> <p>'795 patent, claims 29-36.</p> <p>Random House Webster's College Dictionary, 2nd edition, 2001, page 1190.</p>	<p>concentration, sterility, osmolarity, and lidocaine concentration, after being stored at about 25C for about two months</p>	<p>including:</p> <p>Office Action dated 5/31/2011;</p> <p>Response to Office Action dated 11/9/2011;</p> <p>Office Action dated 2/3/2012;</p> <p>Response to Office Action dated 7/30/2012;</p> <p>Office Action dated 11/19/2012;</p> <p>Applicant Initiated Interview Summary on 2/6/2013;</p> <p>Response to Final Office Action dated 2/19/2013.</p> <p><u>EXTRINSIC</u></p>
--	--	--	---	--	---

			<p>[AGNHA00096822-96827 at 96826]</p> <p>Oxford Concise English Dictionary, 11th edition, 2008, page 1402.</p> <p>[AGNHA00096817-96821at 96820]</p>		
--	--	--	---	--	--

Exhibit B

The Parties' Proposed Constructions of Disputed Claim Terms and Supporting Evidence
for U.S. Patent No. 8,357,795

Disputed Claim Terms	Claim No.	Allergan's Proposed Construction	Allergan's Supporting Evidence	Defendants' Proposed Construction	Defendants' Supporting Evidence
hyaluronic acid (HA) component crosslinked with a crosslinking agent	(Claim 1)	HA that forms a macromolecular structure resulting from chemical linking of HA by a crosslinking agent	<p><u>INTRINSIC</u> Claims 1, 4, 5, 12, 22, 23, Col. 1, ll. 23-34, 66-67, Col. 2, ll. 7-19, 50-58, Col. 3, ll. 7-19, 22-41, 62-65, Col. 4, ll. 5-30, 13-29, Col. 5, ll. 43-46, 53-61, Col. 8, ll. 20-24, Col. 9, l. 64 to Col. 10, l. 15, Example 2, Col. 10, ll. 16-45, Col. 13, l. 12 to Col. 14, l. 25.</p> <p>Communications from file wrapper of Application No. 12/393,884 including: Office Action dated 5/31/2011;</p>	HA that has been covalently modified with a crosslinking agent to form a macromolecular structure that is water-insoluble, such that the degree of crosslinking is at least about 2% and is up to about 20%.	<p><u>INTRINSIC</u> <u>2:50-58;</u> <u>3:10-19;</u> <u>3:66 – 4:1;</u> <u>5:46-52;</u> <u>8:4-25;</u> <u>10:16-24;</u> <u>15:34-37</u></p> <p><u>U.S. Patent No. 8124120 B2</u></p> <p><u>EXTRINSIC</u> <u>VAL0060472</u> <u>at 73 (2:9-16)</u></p>

			<p>Response to Office Action dated 9/29/2011; Office Action dated 12/27/2011; Applicant Initiated Interview Summary dated 1/24/2012; Applicant Initiated Interview Summary dated 4/9/2012; Declaration of Lebreton dated 3/7/2012 and 6/14/2012; Response to Final Office Action dated 6/14/2012.</p> <p><u>EXTRINSIC</u> Merriam-Webster Online Dictionary and Thesaurus, (http://www.merriamwebster.com/). [AGNHA00096828]</p> <p>Random House Webster's College Dictionary, 2nd edition, 2001, page 296. [AGNHA00096824]</p>	<p>construction as agreed by the parties within the '475 Patent.</p>	<p><u>VAL0059980</u> <u>at 81 (2:26-30),</u> <u>82-83 (4:45</u> <u>– 5:3)</u></p> <p><u>VAL0060006</u> <u>at</u> <u>VAL0060008</u> <u>(3:14-18),</u> <u>VAL0060013</u> <u>(8:1-9)</u></p> <p><u>VAL0060285</u> <u>at 87 ([0011])</u></p>
--	--	--	--	--	--